- theory and concepts
- decision theory
- decision psychology
- probability/bayes
- preferences/values
- priority setting/ethics
- costing methods
- approaches and applications
- decision analysis
- risk analysis
- benefit-cost analysis
- cost-effectiveness analysis
- technology assessment
- operations research
- infectious diseases
- child/nutrition
- social determinants
- policy/regulation
- north america
Resources Repository
-
ReviewPublication 2015Medicare's Use of CEA for Prevention (But Not Treatment)
Medicare currently pays for 23 preventive services in its benefits package, the majority of which …
Medicare currently pays for 23 preventive services in its benefits package, the majority of which were added since 2005. In the past decade, the program has transformed from one essentially administering treatment claims, to one increasingly focused on health promotion and maintenance. What is largely unappreciated is the role cost-effectiveness analysis has played in the coverage of preventive services. This study reviews the role of cost-effectiveness analysis in Medicare coverage of preventive services and contrast it…
Priority Setting/Ethics | Technology Assessment | Cost-Effectiveness Analysis | North America | Policy/Regulation | Child/Nutrition | Infectious Diseases | Chronic Disease/Risk | Health Systems | Economics/Finance | Government/Law | Health/Medicine -
ReviewPublication 2016Strengthening Cost-Effectiveness Analysis for Public Health Policy
Many important opportunities to improve health lie outside the health sector and involve improving the …
Many important opportunities to improve health lie outside the health sector and involve improving the conditions in which we live and work: safe design and maintenance of roads, bridges, train tracks, and airports; control of environmental pollutants; occupational safety; healthy buildings; a safe and healthy food supply; safe manufacture of consumer products; a healthy social environment; and others. Faced with the overwhelming array of possibilities, U.S. decision makers need help identifying those that can contribute the…
Priority Setting/Ethics | Preferences/Values | Cost-Effectiveness Analysis | Costing Methods | North America | Policy/Regulation | Social Determinants | Environmental Health | Health Systems | Climate/Environment | Economics/Finance | Food/Agriculture | Health/Medicine -
ReportPublication 2021Valuing COVID-19 Mortality and Morbidity Risks
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk …
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk reductions that builds on the U.S. Department of Health and Human Services (HHS) Guidelines for Regulatory Impact Analysis. They review the differences between COVID-19 mortality risks and the types of risks that are more commonly studied, and find that the impacts of these differences on the value of mortality risk reductions (the value per statistical life, VSL) are uncertain. They…
Preferences/Values | Benefit-Cost Analysis | North America | Policy/Regulation | Infectious Diseases | Government/Law -
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Probability/Bayes | Technology Assessment | North America | Policy/Regulation | Infectious Diseases | Test Performance | Health Systems | Government/Law | Health/Medicine | Global -
ReportPublication 2017Communicating Science Effectively: A Research Agenda
Science and technology are embedded in virtually every aspect of modern life. As a result, …
Science and technology are embedded in virtually every aspect of modern life. As a result, people face an increasing need to integrate information from science with their personal values and other considerations as they make important life decisions about medical care, the safety of foods, what to do about climate change, and many other issues. Communicating science effectively, however, is a complex task and an acquired skill. Moreover, the approaches to communicating science that will…
Priority Setting/Ethics | Preferences/Values | Decision Psychology | North America | Social Determinants | Climate/Environment | Culture/Society | Energy/Engineering | Education/Labor | Health/Medicine | Science/Technology -
ReportPublication 2021What the American Public Thinks About Vaccines and How Framing Can Help
This paper explores the question of public understandings, beliefs, and attitudes about vaccination in general, …
This paper explores the question of public understandings, beliefs, and attitudes about vaccination in general, and childhood vaccination more specifically. The authors provide an overview of the existing literature on public thinking about vaccination and on effective communication strategies and interventions that have been either suggested or empirically tested. This description was extracted from the publication abstract.
Preferences/Values | North America | Social Determinants | Child/Nutrition | Infectious Diseases | Culture/Society | Health/Medicine | Science/Technology -
ReportPublication 2017Underestimated Cost of the Opioid Crisis
This report on the opioid public health crisis was released by the White House Council …
This report on the opioid public health crisis was released by the White House Council on Economic Advisors (CEA) in November 2017. It corrects previous estimates of related costs by adding the value of the associated deaths. Earlier estimates focused on medical and other expenditures, while the new report also includes estimates of the value that individuals place on reducing their own risks of premature mortality. The report notes that, in 2015, over 33,000 Americans…
Preferences/Values | Benefit-Cost Analysis | Costing Methods | North America | Policy/Regulation | Chronic Disease/Risk | Mental Health | Economics/Finance | Government/Law | Health/Medicine -
ReportPublication 2015Opioid Dependence: Final Report
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value …
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value of interventions for the management of opioid dependence. The goals of the report are to document the federal and New England state regulations affecting treatment options, provide an overview of existing clinical guidelines and payer coverage policies, and summarize the evidence on the different management approaches for opioid dependence, including special considerations for adolescents. An appendix is provided by ICER.…
Preferences/Values | Technology Assessment | Cost-Effectiveness Analysis | North America | Policy/Regulation | Health Outcomes | Evidence Synthesis | Chronic Disease/Risk | Mental Health | Health Systems | Business/Industry | Government/Law | Health/Medicine | Science/Technology -
ReviewPublication 2022Systematic Review of Economic Evaluations of COVID-19 Interventions: Non-Health Impacts and Distributional Issues
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether …
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether they incorporated non-health impacts and distributional concerns. Among the 70 articles included, more than half (56%) included at least one non-health impact, although only 21% incorporated non-economic consequences. Only 17% examined subgroups of interest. The median ICER for the entire sample was $67,000/quality-adjusted life-year (QALY) (interquartile range [IQR] $9000-$893,000/QALY). Interventions including a pharmaceutical component yielded a median ICER of $93,000/QALY (IQR…
Cost-Effectiveness Analysis | North America | Social Determinants | Infectious Diseases | Evidence Synthesis | Culture/Society | Economics/Finance | Health/Medicine